Mega Genomics Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Mega Genomics's earnings have been declining at an average annual rate of -29.3%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 8.7% per year. Mega Genomics's return on equity is 4.8%, and it has net margins of 20%.
Belangrijke informatie
-29.3%
Groei van de winst
n/a
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 11.3% |
| Inkomstengroei | 8.7% |
| Rendement op eigen vermogen | 4.8% |
| Nettomarge | 20.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Shareholders Will Be Pleased With The Quality of Mega Genomics' (HKG:6667) Earnings
Oct 03
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Opbrengsten en kosten
Hoe Mega Genomics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 160 | 32 | 59 | 0 |
| 31 Mar 24 | 156 | 31 | 60 | 0 |
| 31 Dec 23 | 151 | 30 | 61 | 0 |
| 30 Sep 23 | 149 | 15 | 82 | 0 |
| 30 Jun 23 | 147 | 0 | 103 | 0 |
| 31 Mar 23 | 146 | -9 | 103 | 0 |
| 31 Dec 22 | 146 | -18 | 104 | 0 |
| 30 Sep 22 | 192 | 22 | 84 | 0 |
| 30 Jun 22 | 238 | 62 | 65 | 0 |
| 31 Mar 22 | 238 | 70 | 58 | 0 |
| 31 Dec 21 | 237 | 79 | 52 | 0 |
| 31 Dec 20 | 203 | 79 | 35 | 0 |
| 31 Dec 19 | 124 | 30 | 27 | 0 |
Kwaliteitswinsten: 6667 has high quality earnings.
Groeiende winstmarge: 6667 became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 6667's earnings have declined by 29.3% per year over the past 5 years.
Versnelling van de groei: 6667 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: 6667 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-16.9%).
Rendement op eigen vermogen
Hoge ROE: 6667's Return on Equity (4.8%) is considered low.